To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Enrollment
21
Study participants will be allocated to receive oral administration of 200 mg cilostazol.
Study participants will be allocated to receive oral administration of placebo.
Danish Headache Center
Copenhagen, Denmark
RECRUITINGIncidence of Migraine-Like Headache
Difference in incidence of headache with migraine-like features (0 to 12 hours) between cilostazol and placebo.
Time frame: 12 Hours
Headache Intensity Scores
Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between cilostazol and placebo.
Time frame: 12 Hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.